Clinical Trials Logo

Carcinoma, Ovarian Epithelial clinical trials

View clinical trials related to Carcinoma, Ovarian Epithelial.

Filter by:

NCT ID: NCT06055348 Not yet recruiting - Clinical trials for Advanced Ovarian Cancer

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Start date: October 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A phase Ib/II clinical study on the safety, pharmacokinetic characteristics, and preliminary efficacy of SC0191 combination chemotherapy in patients with advanced ovarian cancer.

NCT ID: NCT06018935 Not yet recruiting - Ovarian Cancer Clinical Trials

A Cohort Establishment Study of Total Management of Ovarian Cancer

Start date: January 1, 2024
Phase:
Study type: Observational

A cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

NCT ID: NCT06017557 Not yet recruiting - Clinical trials for Ovarian Cancer Stage IV

Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR)

PREDAtOOR
Start date: June 29, 2024
Phase: N/A
Study type: Interventional

PREDAtOOR is a pilot study and this study aims at improving the selection of the best treatment strategy for patients with advanced ovarian cancer by using Camera Vision (CV) to predict outcomes of cyto reduction at the time of Diagnostic laparoscopy.

NCT ID: NCT06010667 Not yet recruiting - Clinical trials for Epithelial Ovarian Cancer

A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer

Start date: September 1, 2023
Phase:
Study type: Observational

The primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with Envafolimab in the treatment of recurrent epithelial ovarian cancer (EOC), fallopian tube cancer, and primary peritoneal cancer.

NCT ID: NCT05991752 Not yet recruiting - Clinical trials for Epithelial Ovarian Cancer

Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial

ROMECO
Start date: November 2023
Phase: N/A
Study type: Interventional

In this study, we hypothesize that calculating the ROMA score (CA125 + HE4 blood marker assay) will enable faster, more targeted diagnosis and management of epithelial ovarian cancer recurrence than the CA125 marker assay alone. This early identification of recurrence would then improve patients' quality of life, since it would increase the chances of benefiting from less invasive and less morbid surgery. It would also reduce the cost of patient management following disease progression. If our hypothesis is confirmed, the results of this study will enable us to update the recommendations for post-treatment follow-up of patients in remission from epithelial ovarian cancer, as well as reimbursing the HE4 marker assay (and thus the calculation of the ROMA score).

NCT ID: NCT05990192 Not yet recruiting - Clinical trials for Ovarian Cancer Recurrent

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

SOPRANO
Start date: January 2024
Phase: Phase 2
Study type: Interventional

SOPRANO is a multi-centre, randomised phase II trial which aims to assess the impact of Stereotactic radiotherapy (SBRT) and continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.

NCT ID: NCT05976932 Not yet recruiting - Ovarian Cancer Clinical Trials

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

Start date: August 2023
Phase:
Study type: Observational

This observational study is conducted to assess the utility of circulating tumor DNA in monitoring the response to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer,and evaluate the consistency of circulating tumor DNA with imaging and CA125 in platinum-resistant ovarian cancer.

NCT ID: NCT05965141 Not yet recruiting - Ovarian Cancer Clinical Trials

Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer

Start date: August 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective phase II, single-center, single-arm clinical study of platinum-sensitive relapsed ovarian cancer. The main objective of this study is to evaluate the efficacy, safety and tolerability of Aribrine combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive relapsed ovarian cancer.

NCT ID: NCT05956093 Not yet recruiting - Clinical trials for High Grade Serous Ovarian Cancer (HGSOC)

68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study

FAST HOC
Start date: May 25, 2024
Phase: N/A
Study type: Interventional

The investigator will use a technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data are gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre. The purpose of this study is to find out if the use of 68Ga-PNT6555 (FAPI) PET-CT will improve the assessment of disease extent as compared to routine CT scans.

NCT ID: NCT05952453 Not yet recruiting - Ovarian Cancer Clinical Trials

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Start date: May 26, 2024
Phase: Phase 2
Study type: Interventional

this is a trial evaluating three chemotherapy agents in patients with newly diagnosed ovarian cancer patients that are Stage III or Stage IV prior to surgery to remove the tumor. After surgery there will be additional chemotherapy given.